Premium
Characteristics of US adults with the metabolic syndrome and therapeutic implications
Author(s) -
Jacobson T. A.,
Case C. C.,
Roberts S.,
Buckley A.,
Murtaugh K. M.,
Sung J. C. Y.,
Gause D.,
Varas C.,
Ballantyne C. M.
Publication year - 2004
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1462-8902.2004.00354.x
Subject(s) - metabolic syndrome , national health and nutrition examination survey , medicine , national cholesterol education program , obesity , cholesterol , clinical trial , endocrinology , population , environmental health
Background: The third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program defines clinical criteria for diagnosis of the metabolic syndrome, which increases cardiovascular risk and is a target for therapy. Aim: We analysed the third National Health and Nutrition Examination Survey (NHANES III; 1988–94) to determine how many US adults meet these criteria and are recommended for lipid‐modifying drug therapy by ATP III. Methods: NHANES III data were used to estimate the number of individuals with the metabolic syndrome and the number recommended for treatment by ATP III, based on 1990 census data. Results: An estimated 36.3 million (23%) US adults have the metabolic syndrome. Of these, 84% met the criterion for obesity, 76% for blood pressure, 75% for HDL‐C, 74% for triglycerides and 41% for glucose. Most (54%) are in the higher risk categories of ATP III, yet only 39% overall are recommended for drug therapy by ATP III cutpoints; of these, most will achieve LDL‐C targets with reductions of 35–40%. Of the 15.3 million individuals with the metabolic syndrome and triglycerides ≥2.26 mmol/l (200 mg/dl), non‐HDL‐C is above ATP III recommendations in 11.6 million. Conclusions: Of the large number of Americans with the metabolic syndrome, ATP III recommends drug therapy for only a minority, because LDL‐C typically is not substantially elevated. Instead, high triglycerides and low HDL‐C are more common; clinical trial data are needed to determine whether optimal therapy should focus on reductions in LDL‐C or on comprehensive improvements to the lipid profile.